From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence In a $200B+ market crowded with black-box AI, BullFrog AI's bfLEAP™ delivers what others can't: biologically grounded, composition-aware analytics that guide smarter therapeutic decisions GAITHERSBURG, Md., July 22, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using art ...

Core Insights - BullFrog AI Holdings, Inc. is hosting a webinar on July 23, 2025, to discuss its advancements in drug development using AI and machine learning [1][2] - The company has launched the BullFrog Data Networks™ Solutions Library, which includes the bfLEAP™ causal AI engine and the new bfPREP™ module for data automation [2] - BullFrog AI is collaborating with Sygnature Discovery to enhance its global reach and drive revenue growth in the $204 billion biopharma R&D market [2] Company Overview - BullFrog AI utilizes AI and machine learning to improve drug discovery and development processes [5] - The company aims to reduce clinical trial failure rates by analyzing complex biological data through its proprietary platforms [5] Webinar Details - The webinar will feature insights from BullFrog AI's Founder and CEO, Vin Singh, followed by a live Q&A session [2][3] - Registration for the free webinar is available online [4]

Core Insights - BullFrog AI Holdings, Inc. has introduced bfPREP™, a data cleansing and preparation module aimed at addressing the multi-billion-dollar data quality challenge in life sciences by automating data processes for AI readiness [1][3] Industry Overview - The global market for data preparation and cleansing tools in life sciences and healthcare is projected to grow from approximately $3.1 billion in 2024 to $6.8 billion by 2029, driven by increasing data volumes and demand for AI-ready infrastructure [3] Product Features - bfPREP™ automates the detection, correction, standardization, and transformation of clinical, omics, and real-world datasets, converting raw information into analysis-ready insights [2][3] - The module is designed for end-to-end automation, significantly reducing data preparation timelines from months to days [5] - It supports standards-based interoperability, with native support for OMOP and plans for additional healthcare data standards [5] Strategic Value - bfPREP™ is tailored for various stakeholders in drug development, including clinical operations teams, contract research organizations (CROs), biotechs, and health IT managers, enhancing their ability to deliver cleaner, submission-ready data faster [5][6] - The solution integrates seamlessly with existing data lakes and supports hybrid environments, making it scalable and cloud-ready [5]